Skip to main content
. 2015 Aug 8;4:81–84. doi: 10.1016/j.bbacli.2015.08.001

Table 1.

Prevalence of antibodies in the autism cohort.

Antigen Typically developing (N = 55) seropositivity Developmental delay (N = 25) seropositivity ASD (N = 103) seropositivitya
GAD-65 0/55 0/25 0/103
Ro52 0/55 0/25 0/103
GFAP 2/55 2/25 4/103
AQP-4 3/55 0/25 5/103
TH 1/55 0/25 1/103
γ-Enolase 1/55 0/25 2/103
XMRV gag 1/55 0/25 0/103
MMTV p24 1/55 0/25 0/103
a

Fisher exact tests revealed no statistical difference in prevalence of antibodies against the eight targets in ASD compared to typically developing and developmental delay children.